23-115: Ascent 05 - 23-115
Summary
| Principal Investigator | Balic, Marija |
|---|---|
| Title | A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice in Patients with Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy |
| Status | Open |
| Locations |
IRMC Cancer Center, in partnership with UPMC Hillman Cancer Center St. Clair Hospital Cancer Center, affiliated with UPMC Hillman Cancer Center UPMC Hillman Cancer Center at Rocco and Nancy Ortenzio Cancer Pavilion (Radiation Oncology) UPMC Hillman Cancer Center at UPMC Magee-Womens Hospital UPMC Hillman Cancer Center at UPMC Passavant–McCandless UPMC Hillman Cancer Center, Erie (Medical Oncology) UPMC Hillman Cancer Center, Harrisburg UPMC Hillman Cancer Center, Independence Health System, Greensburg UPMC Hillman Cancer Center, Monroeville (Medical Oncology) |
| Treatment Type | Treatment |
| Applicable Disease Sites |
Breast Triple Negative Breast Cancer |
| Drugs Involved |
Capecitabine Pembrolizumab Sacituzumab govitecan |
| NCT # | NCT05633654 |
| ClinicalTrials.gov | https://clinicaltrials.gov/study/NCT05633654 |
